WO2015154012A8 - Clonogenic natural killer (nk) cell populations and methods of producing and using such populations - Google Patents

Clonogenic natural killer (nk) cell populations and methods of producing and using such populations Download PDF

Info

Publication number
WO2015154012A8
WO2015154012A8 PCT/US2015/024315 US2015024315W WO2015154012A8 WO 2015154012 A8 WO2015154012 A8 WO 2015154012A8 US 2015024315 W US2015024315 W US 2015024315W WO 2015154012 A8 WO2015154012 A8 WO 2015154012A8
Authority
WO
WIPO (PCT)
Prior art keywords
clonogenic
cells
cell
present
methods
Prior art date
Application number
PCT/US2015/024315
Other languages
French (fr)
Other versions
WO2015154012A1 (en
Inventor
Gianfranco PITTARI
Annamalai SELVAKUMAR
Xiao-rong LIU
Bo Dupont
Original Assignee
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center filed Critical Memorial Sloan-Kettering Cancer Center
Publication of WO2015154012A1 publication Critical patent/WO2015154012A1/en
Publication of WO2015154012A8 publication Critical patent/WO2015154012A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to novel methods for in vitro expansion of clonogenic natural killer (NK) cells. The methods utilize the stimulatory effects of trans-presented IL-15 in cell culture using feeder cells to expand isolated NK cell clones with a predetermined phenotypic trait of interest. The resultant clonogenic NK cell populations are homogenous, in contrast to heterogenous, crude NK cells typically isolated and expanded from a human tissue sample. The present invention also relates to feeder cells that are genetically engineered to trans-present IL-15 involving co-expressing human IL-15 and IL-15 receptor α subunit (IL-15Rα) that are capable of stimulating the expansion of NK cell clones in vitro. The present invention further relates to viable, functional clonogenic NK cell populations with the predetermined phenotypic trait of interest obtained via the above in vitro expansion methods and their use in personalized medicine to treat diseases, including leukemia, lymphoma and human hematopoietic cell transplantation (HCT), in drug screening and in basic and translational studies involving NK cells.
PCT/US2015/024315 2014-04-03 2015-04-03 Clonogenic natural killer (nk) cell populations and methods of producing and using such populations WO2015154012A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974946P 2014-04-03 2014-04-03
US61/974,946 2014-04-03

Publications (2)

Publication Number Publication Date
WO2015154012A1 WO2015154012A1 (en) 2015-10-08
WO2015154012A8 true WO2015154012A8 (en) 2016-06-16

Family

ID=54241338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/024315 WO2015154012A1 (en) 2014-04-03 2015-04-03 Clonogenic natural killer (nk) cell populations and methods of producing and using such populations

Country Status (1)

Country Link
WO (1) WO2015154012A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
WO2016197108A1 (en) * 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
CN105567634A (en) * 2016-01-27 2016-05-11 上海润泉生物技术有限公司 Culture medium and method for NK cell expansion in vitro
CN108700566A (en) 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 The method that immunogenicity is adjusted
EP3565565A4 (en) * 2017-01-04 2020-12-09 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
CN107573419A (en) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 A kind of nucleic acid molecules for strengthening T cell antitumor activity
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP6647240B2 (en) * 2017-05-12 2020-02-14 米満　吉和 Highly active NK cells and their use
WO2018213828A1 (en) * 2017-05-19 2018-11-22 Case Western Reserve University Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof
WO2019152663A1 (en) * 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN111757745B (en) 2018-02-01 2022-11-04 Nkmax有限公司 Methods of producing natural killer cells and compositions for treating cancer
WO2019165097A1 (en) * 2018-02-21 2019-08-29 Board Of Regents,The University Of Taxas System Universal antigen presenting cells and uses thereof
WO2020036934A1 (en) * 2018-08-13 2020-02-20 The Regents Of The University Of Michigan Methods for treating amyotrophic lateral sclerosis
BR112021004465A2 (en) * 2018-09-10 2021-05-25 Atara Biotherapeutics, Inc. methods for expanding antigen-specific car-t cells, compositions and related uses
WO2020172328A1 (en) * 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112391349B (en) * 2019-08-19 2023-05-23 刘韬 Trophoblast cell strain, preparation method thereof and method for in-vitro induction amplification of NK cells
US20210077527A1 (en) * 2019-09-13 2021-03-18 The Research Institute At Nationwide Children's Hospital Universal donor selection method to identify nk-cell-donors
WO2021051088A1 (en) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
WO2021202232A1 (en) * 2020-03-28 2021-10-07 Board Of Regents, The University Of Texas System Cell immunotherapy for the treatment of cancer
CN111424012A (en) * 2020-03-30 2020-07-17 威海市中心医院 Treatment method for feeder cell proliferation removing capacity for NK cell culture
CN117535241B (en) * 2024-01-10 2024-04-30 浙江康佰裕生物科技有限公司 NK feeding monoclonal cell line and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518397B2 (en) * 2009-08-14 2013-08-27 Case Western Reserve University Notch induced natural killer cell generation and therapeutic uses
US11471486B2 (en) * 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells

Also Published As

Publication number Publication date
WO2015154012A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
MX2020009359A (en) Therapeutic cell systems and methods for treating cancer and infectious diseases.
Liu et al. MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6
EP4083063A3 (en) Antigen-specific immune effector cells
MX2021000607A (en) Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells.
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
SG10201808825XA (en) Defined composition gene modified t-cell products
MX2022003698A (en) Nanoparticle compositions and methods for immunotherapy.
RU2017111300A (en) CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
WO2016026854A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
JP2016509840A5 (en)
BR112016009402A2 (en) PEPTIDE, ACTIVATED CYTOTOXIC T-LYMPHOCYTES (CTL), METHOD FOR THEIR PRODUCTION, ANTIBODY, T-CELL RECEPTOR, NUCLEIC ACID, HOST CELL, USE THEREOF, KIT, METHOD FOR PRODUCING A CUSTOMIZED ANTI-CANCER VACCINE FOR AN INDIVIDUAL PATIENT
MX2015001871A (en) Natural killer cells and uses thereof.
MX2019011570A (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells.
PH12018502402A1 (en) Methods of treating autoimmune disease using allogeneic t cells
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
MA40589A (en) USING JAGGED 1 / FRIZZLED 4 AS CELL SURFACE MARKERS TO ISOLATE HUMAN VENTRICULAR HEART PROGENITOR CELLS
MX2021006393A (en) Methods for ex vivo expansion of natural killer cells and use thereof.
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
MX2020005849A (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof.
ECSP20082338A (en) RECEPTORS OF THE CHIMERICAL GROWTH FACTOR
MX2015017959A (en) Compositions and methods for immunotherapy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773118

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15773118

Country of ref document: EP

Kind code of ref document: A1